首页> 外国专利> Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance

Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance

机译:总和磷酸化的IL-1受体相关激酶1和IL-1受体相关激酶4作为癌症进展和化疗耐药性的生物标记。

摘要

Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma and T-ALL. TLR signaling plays an important role in T cell malignancies and melanoma. The effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma and T-ALL cells were evaluated. Pharmacological treatment with an IRAK-1,-4 inhibitor delays tumor growth and prolongs survival in vitro and in vivo, indicating that TLR signaling contributes to T-ALL and melanoma progression and interfering with this signaling is a novel therapeutic strategy to control T-ALL and melanoma proliferation.
机译:Toll样受体(TLR)由多种癌症表达,包括黑色素瘤和T-ALL。 TLR信号传导在T细胞恶性肿瘤和黑色素瘤中起重要作用。评估了在黑色素瘤和T-ALL细胞中刺激或抑制TLR / IL-1受体相关激酶IRAK-1和IRAK-4的作用。用IRAK-1,-4抑制剂进行药理治疗可延迟肿瘤生长并延长体内和体外存活时间,这表明TLR信号促成T-ALL和黑素瘤的进展,而干扰此信号是控制T-ALL的新治疗策略和黑色素瘤增殖。

著录项

  • 公开/公告号US2013280264A1

    专利类型

  • 公开/公告日2013-10-24

    原文格式PDF

  • 申请/专利权人 UNIVERSITY OF MARYLAND BALTIMORE;

    申请/专利号US201313804135

  • 发明设计人 EDUARDO DAVILA;

    申请日2013-03-14

  • 分类号C12Q1/68;G01N33/68;A61K45/06;A61K39/395;

  • 国家 US

  • 入库时间 2022-08-21 16:51:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号